Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AZD8330

Catalog No: tcsc0217

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
869357-68-6

Formula:
$C_{16}H_{17}FIN_3O_4$

Pathway:
MAPK/ERK Pathway

Target:
MEK

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
ARRY-424704;ARRY-704

Observed Molecular Weight:
461.23

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

AZD8330 (ARRY-424704) is a potent, uncompetitive **MEK1**/**MEK2** inhibitor, with an **IC_{50}** of 7 nM.

IC50 & Target: IC50: 7 nM (MEK1/MEK2)[1]

In Vitro: AZD8330 is a selective allosteric MEK1/ MEK2 inhibitor. Exposing human osteosarcoma cell lines MOS, U2OS, and 143B to a concentration of 0.5 μM of Trametinib, AZD8330 or TAK-733 for 6 hours, leads to loss of ERK phosphorylation indicating effective MEK inhibition.The activity of these three inhibitors is tested using concentration ranges in six osteosarcoma cell lines: MOS, U2OS, KPD, ZK58, 143b and Saos-2. All three inhibitors decrease viability of MOS and U2OS and strongly affect 143b. By contrast, viability of KPD, ZK58 and Saos-2 is not affected by any of the three inhibitors[2].

In Vivo: In tumour xenograft models, AZD8330 demonstrates dose-dependent tumour growth inhibition of approximately 90% at tolerated doses (1.0 mg/kg once daily [OD])[1].